Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Feb 25;60(6):793–808. doi: 10.1007/s00262-011-0989-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2011

Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Fig. 10 — Survival curve in the patients with metastatic lesions (M1) based on the mean values of mRNA levels of serum and tumor lFNAR2 s, and of protein levels of tumor phosphorylated Akt (Ser-473) and phosphorylated S6 ribosomal protein (Ser-235/236), the cases were divided into two groups at this levels—high and low expression. Progression-free survival curve based on serum (a) and tumor IFNAR2 mRNA levels (b) in M1 patients treated with IFN-α ± sorafenib therapy. Progression-free survival curve based on tumor proteins for phosphorylated Akt (Ser-473) (c) and phosphorylated S6 ribosomal protein (Ser-235/236) (d) in M1 patients treated with IFN-α + sorafenib therapy. Overall survival curve based on serum (e) and tumor IFNAR2 mRNA levels (f) in M1 patients treated with IFN-α ± sorafenib therapy. Overall survival curve based on tumor proteins for phosphorylated Akt (Ser-473) (g) and phosphorylated S6 ribosomal protein (Ser-235/236) (h) in M1 patients treated with IFN-α + sorafenib therapy. P value was analyzed by log-rank test